News coverage about VBI Vaccines (NASDAQ:VBIV) has been trending somewhat positive recently, according to Accern Sentiment Analysis. The research firm identifies positive and negative press coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. VBI Vaccines earned a coverage optimism score of 0.15 on Accern’s scale. Accern also assigned news stories about the biopharmaceutical company an impact score of 47.6758849154529 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.

Here are some of the media headlines that may have impacted Accern Sentiment’s analysis:

VBIV has been the topic of several recent analyst reports. BMO Capital Markets cut their price target on shares of VBI Vaccines from $13.00 to $12.00 and set an “outperform” rating on the stock in a report on Friday, July 27th. Zacks Investment Research upgraded shares of VBI Vaccines from a “sell” rating to a “hold” rating in a research note on Thursday, July 26th. Finally, ValuEngine upgraded shares of VBI Vaccines from a “sell” rating to a “hold” rating in a research note on Wednesday, May 2nd. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average price target of $9.08.

VBI Vaccines stock traded down $0.12 during mid-day trading on Friday, reaching $1.91. The stock had a trading volume of 94,833 shares, compared to its average volume of 242,903. VBI Vaccines has a one year low of $1.85 and a one year high of $5.10. The company has a current ratio of 2.75, a quick ratio of 2.69 and a debt-to-equity ratio of 0.14.

VBI Vaccines (NASDAQ:VBIV) last issued its earnings results on Thursday, July 26th. The biopharmaceutical company reported ($0.26) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.17) by ($0.09). VBI Vaccines had a negative return on equity of 53.12% and a negative net margin of 6,175.95%. The business had revenue of $0.23 million during the quarter. equities analysts expect that VBI Vaccines will post -0.85 EPS for the current year.

In other VBI Vaccines news, CEO Jeff Baxter bought 13,500 shares of the firm’s stock in a transaction on Friday, August 3rd. The stock was acquired at an average price of $2.01 per share, with a total value of $27,135.00. Following the transaction, the chief executive officer now owns 224,905 shares in the company, valued at $452,059.05. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. In the last three months, insiders acquired 51,400 shares of company stock valued at $117,982. 54.50% of the stock is owned by insiders.

VBI Vaccines Company Profile

VBI Vaccines Inc, a biopharmaceutical company, develops and sells vaccines to address unmet needs in infectious disease and immuno-oncology in Israel and internationally. The company offers Sci-B-Vac, a third-generation hepatitis B vaccine for adults, children, and newborns; and eVLP, a vaccine platform for the design of enveloped virus-like particle vaccines that closely mimic the target virus.

Recommended Story: Average Daily Trade Volume Explained

Insider Buying and Selling by Quarter for VBI Vaccines (NASDAQ:VBIV)

Receive News & Ratings for VBI Vaccines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VBI Vaccines and related companies with's FREE daily email newsletter.